[{"id":"5bdc28e5-7ca8-447b-ae67-6e292adebde6","acronym":"TRIFOUR","url":"https://clinicaltrials.gov/study/NCT05181462","created_at":"2022-01-06T22:53:40.626Z","updated_at":"2025-02-25T15:12:31.656Z","phase":"Phase 1/2","brief_title":"Nadunolimab in Combination with Gemcitabine Plus Carboplatin in Patients with Advanced Triple Negative Breast Cancer.","source_id_and_acronym":"NCT05181462 - TRIFOUR","lead_sponsor":"Cantargia AB","biomarkers":" HER-2 • PD-L1 • ER • PGR • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" HER-2 negative • HER-2 negative + HR negative • HER-2 negative + HR negative + BRCA mutation","tags":["HER-2 • PD-L1 • ER • PGR • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • HER-2 negative + HR negative • HER-2 negative + HR negative + BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • nadunolimab (CAN04)"],"overall_status":"Recruiting","enrollment":" Enrollment 116","initiation":"Initiation: 01/11/2022","start_date":" 01/11/2022","primary_txt":" Primary completion: 06/15/2025","primary_completion_date":" 06/15/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2025-02-13"},{"id":"257cca5a-c910-4b83-b699-e799dee41eab","acronym":"","url":"https://clinicaltrials.gov/study/NCT03101748","created_at":"2021-01-18T15:16:53.226Z","updated_at":"2025-02-25T13:52:17.471Z","phase":"Phase 1/2","brief_title":"Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer","source_id_and_acronym":"NCT03101748","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • HER-2 negative + HR negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • HER-2 negative + HR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • Nerlynx (neratinib) • Perjeta (pertuzumab) • doxorubicin hydrochloride • cyclophosphamide • Herzuma (trastuzumab-pkrb) • daunorubicin • Ontruzant (trastuzumab-dttb) • Ogivri (trastuzumab-dkst) • Trazimera (trastuzumab-qyyp) • Herwenda (trastuzumab biosimilar) • GB221 (coprelotamab) • SIBP-01 (trastuzumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 01/29/2018","start_date":" 01/29/2018","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-12-13"},{"id":"a6261b4d-283f-45db-9b03-c83871bfbd02","acronym":"","url":"https://clinicaltrials.gov/study/NCT02957968","created_at":"2021-01-18T14:31:51.880Z","updated_at":"2025-02-25T16:05:24.919Z","phase":"Phase 2","brief_title":"Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca","source_id_and_acronym":"NCT02957968","lead_sponsor":"Virginia Commonwealth University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HR positive • HER-2 negative • HER-2 negative + HR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • HER-2 negative + HR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • doxorubicin hydrochloride • azacitidine • albumin-bound paclitaxel • cyclophosphamide • decitabine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 01/24/2017","start_date":" 01/24/2017","primary_txt":" Primary completion: 08/04/2022","primary_completion_date":" 08/04/2022","study_txt":" Completion: 02/28/2025","study_completion_date":" 02/28/2025","last_update_posted":"2024-11-11"},{"id":"9d2cfc9b-82d5-496a-9443-80543cf607c5","acronym":"SMA-BC-002","url":"https://clinicaltrials.gov/study/NCT05978648","created_at":"2023-08-07T14:08:51.211Z","updated_at":"2025-02-25T12:29:41.505Z","phase":"Phase 2","brief_title":"Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy","source_id_and_acronym":"NCT05978648 - SMA-BC-002","lead_sponsor":"wang shusen","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • ER negative • HER-2 negative + HR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • ER negative • HER-2 negative + HR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • paclitaxel • docetaxel • Perjeta (pertuzumab) • cyclophosphamide • epirubicin • Cosela (trilaciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 116","initiation":"Initiation: 09/20/2023","start_date":" 09/20/2023","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2023-11-30"},{"id":"9f5f5828-6d10-4094-880b-322fc5ecbb08","acronym":"","url":"https://clinicaltrials.gov/study/NCT05983094","created_at":"2023-08-09T14:09:24.106Z","updated_at":"2025-02-25T12:29:42.410Z","phase":"Phase 2","brief_title":"Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer","source_id_and_acronym":"NCT05983094","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • HER-2 negative + HR negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • HER-2 negative + HR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • Perjeta (pertuzumab) • epirubicin • utidelone IV (UTD1)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 181","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2023-08-09"},{"id":"96e68fcf-5c3b-47ce-b8b1-3c86e2210d1d","acronym":"PANGEA","url":"https://clinicaltrials.gov/study/NCT03025880","created_at":"2021-01-18T14:53:32.501Z","updated_at":"2025-02-25T16:05:44.348Z","phase":"Phase 2","brief_title":"Trial to Evaluate Efficacy and Safety of Pembrolizumab and Gemcitabine in HER2-negative ABC","source_id_and_acronym":"NCT03025880 - PANGEA","lead_sponsor":"Spanish Breast Cancer Research Group","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HR positive • HER-2 negative • HER-2 expression • HER-2 negative + HR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • HER-2 expression • HER-2 negative + HR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • gemcitabine"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 06/28/2017","start_date":" 06/28/2017","primary_txt":" Primary completion: 06/03/2019","primary_completion_date":" 06/03/2019","study_txt":" Completion: 07/22/2021","study_completion_date":" 07/22/2021","last_update_posted":"2023-04-03"},{"id":"9c0847ac-5801-440b-a0e4-5bffd43dfd55","acronym":"","url":"https://clinicaltrials.gov/study/NCT03412643","created_at":"2021-01-18T16:50:12.669Z","updated_at":"2025-02-25T12:26:51.280Z","phase":"Phase 2","brief_title":"Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling","source_id_and_acronym":"NCT03412643","lead_sponsor":"NSABP Foundation Inc","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HR positive • HER-2 negative • HER-2 negative + HR negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • HER-2 negative + HR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • Perjeta (pertuzumab) • doxorubicin hydrochloride • cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 05/14/2018","start_date":" 05/14/2018","primary_txt":" Primary completion: 10/30/2023","primary_completion_date":" 10/30/2023","study_txt":" Completion: 10/30/2023","study_completion_date":" 10/30/2023","last_update_posted":"2023-03-06"},{"id":"5b43b105-ae0b-4a8b-b154-10d8e221fff1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04762901","created_at":"2021-02-21T13:52:25.679Z","updated_at":"2025-02-25T13:19:55.631Z","phase":"Phase 1","brief_title":"LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer","source_id_and_acronym":"NCT04762901","lead_sponsor":"Wake Forest University Health Sciences","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 negative • HER-2 negative + HR negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 negative • HER-2 negative + HR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • doxorubicin hydrochloride • Zejula (niraparib) • cyclophosphamide • Neulasta (pegfilgrastim)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 04/01/2021","start_date":" 04/01/2021","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2022-04-26"},{"id":"2c99ae6c-422d-443e-9669-6670f7abcae8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03430518","created_at":"2021-01-18T16:55:21.096Z","updated_at":"2025-02-25T13:35:02.735Z","phase":"Phase 1","brief_title":"Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer","source_id_and_acronym":"NCT03430518","lead_sponsor":"Amy Tiersten","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative • HER-2 negative + HR negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • HER-2 negative + HR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Halaven (eribulin mesylate)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 05/17/2018","start_date":" 05/17/2018","primary_txt":" Primary completion: 02/10/2020","primary_completion_date":" 02/10/2020","study_txt":" Completion: 02/10/2020","study_completion_date":" 02/10/2020","last_update_posted":"2020-08-05"}]